Literature DB >> 19464082

[Metformin also as first choice in patients with normal weight. Has its use increased?].

Eduardo Carracedo-Martínez1, Agustin Pia-Morandeira.   

Abstract

OBJECTIVE: To assess whether the release of the new consensus algorithms in August 2006, along with the consensus recommendation of also using metformin as first choice in patients with normal weight, has led to an increase in the use of this drug in the period immediately after.
DESIGN: Retrospective longitudinal Study. SITES: Santiago de Compostela Health District (A Coruña). PARTICIPANTS: Users of the Galician health service in the Santiago de Compostela Health District.
METHODS: The evolution of the monthly number of DHD (Daily Defined Doses/1000 inhabitants/day) of metformin from early 2003 until 12 months after the issuing of new algorithms was analysed graphically and using a multiple regression model.
RESULTS: The graphical representation of the DHD of metformin over time shows a linear growth for the period, but there is an increasing trend after the publication of the new consensus algorithm. The multiple regression showed that the increase is statistically significant.
CONCLUSIONS: Following the publication of the new consensus algorithm an increasing trend in the use of metformin is observed in the short term.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464082      PMCID: PMC7022010          DOI: 10.1016/j.aprim.2008.10.010

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  14 in total

1.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

Authors:  M Hanefeld; M Cagatay; T Petrowitsch; D Neuser; D Petzinna; M Rupp
Journal:  Eur Heart J       Date:  2004-01       Impact factor: 29.983

2.  No evidence for a reduction of myocardial infarctions by acarbose.

Authors:  Floris A van de Laar; Peter L B J Lucassen
Journal:  Eur Heart J       Date:  2004-07       Impact factor: 29.983

3.  The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus.

Authors:  René Lub; Petra Denig; Paul B van den Berg; Klaas Hoogenberg; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

4.  Thiazolidinediones for initial treatment of type 2 diabetes?

Authors:  David M Nathan
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

5.  The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.

Authors:  L A Donnelly; A S F Doney; A T Hattersley; A D Morris; E R Pearson
Journal:  Diabet Med       Date:  2006-02       Impact factor: 4.359

6.  [Comparison of the prevalence of diabetes mellitus among different areas from Spain].

Authors:  F Javier Basterra-Gortari; Miguel Angel Martínez-González
Journal:  Med Clin (Barc)       Date:  2007-11-17       Impact factor: 1.725

Review 7.  [Evolution of prevalence of type 2 diabetes in adult Spanish population].

Authors:  Sergio Valdés; Gemma Rojo-Martínez; Federico Soriguer
Journal:  Med Clin (Barc)       Date:  2007-09-15       Impact factor: 1.725

8.  A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

Authors:  R R Holman; C A Cull; R C Turner
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

9.  Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

10.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.